DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING ANTI-C5 CROVALIMAB ANTIBODY Russian patent published in 2024 - IPC A61K39/395 C07K16/18 A61P7/00 A61P37/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmaceutics, namely to a method of treating or preventing paroxysmal nocturnal haemoglobinuria (PNH) in a subject having a body weight equal to or greater than 100 kg, comprising (i) intravenous administration of a loading dose of 1500 mg of the anti-C5 antibody to the subject once; (ii) a subcutaneous loading dose of 340 mg of the anti-C5 antibody to subject 1 day after the start of the intravenous administration of the anti-C5 antibody; (iii) a subcutaneous loading dose of 340 mg of the anti-C5 antibody to subject 1 week, 2 weeks and 3 weeks after the start of the intravenous administration of the anti-C5 antibody once a week; (iv) subcutaneous administration of a maintenance dose of 1020 mg of the anti-C5 antibody to subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody; and (v) subcutaneous administration of a maintenance dose of 1020 mg of the anti-C5 antibody to the subject several times at 4-week intervals, wherein the anti-C5 antibody is Crovalimab.

EFFECT: providing transition from intravenous to subcutaneous administration, reducing formation of drug-target-drug complexes (DTDC) in patients.

8 cl, 13 dwg, 1 tbl, 7 ex